Medesis Pharma
France - BaillarguesPharmaceutical
Focus: Medesis Pharma is a French pharmaceutical company specializing in innovative drug delivery platforms for buccal administration, blood-brain barrier penetration, and challenging APIs including RNAi, peptides, and metal ions. The company operates in the gene therapy space with a focus on enabling drug delivery rather than commercialized products.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
0
About Medesis Pharma
AI assessmentNot HiringNo open roles listed right now. Follow Medesis Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Placebo
COVID-19 PandemicClinical Trials (1)
NCT05451654NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)
Phase 1/2Help build intelligence for Medesis Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.